DEA - Medical Cannabis Brief

Congresswoman To DEA: ‘Reject Any Argument’ That Marijuana Rescheduling Violates US Treaty Obligations

Medical Marijuana Program Connection

FEBRUARY 27, 2024

urged the Drug Enforcement Administration (DEA) to refute any assertions that suggested rescheduling marijuana at the federal level would breach international treaty obligations. In a letter to DEA administrator Anne Milgram, Kamlager-Dove stressed international treaties neither mandate the inclusion of marijuana in Schedule I or II.

DEA

DEA Marijuana Legalization Cannabis

DEA’s Cannabis Classification: Time To Right A Decades-Old Mistake As Feds Confirm Marijuana’s Medical Benefits

Medical Marijuana Program Connection

JANUARY 14, 2024

Schedule I drugs are defined by the DEA as substances with no “currently accepted medical use and a high potential for abuse.” The list includes heroin, LSD, ecstasy, meth, peyote, and, for the past 24 years, cannabis. With Friday’s release of documents related to the Department of Health and Human Service’s (HHS). Read More

DEA

DEA Cannabis Legalization

FDA Gathers Public Social Media Data To Better Understand Cannabis Users As Part Of Its Effort Toward Rescheduling Marijuana

Medical Marijuana Program Connection

FEBRUARY 20, 2024

The Food and Drug Administration recently offered a glimpse into its comprehensive analysis justifying its recommendation to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act.

Media

Media Data Marijuana Food

Congresswoman To DEA: ‘Reject Any Argument’ That Marijuana Rescheduling Violates US Treaty Obligations

DEA’s Cannabis Classification: Time To Right A Decades-Old Mistake As Feds Confirm Marijuana’s Medical Benefits

FDA Gathers Public Social Media Data To Better Understand Cannabis Users As Part Of Its Effort Toward Rescheduling Marijuana

Stay Connected